Innate Pharma (IPHA)
(Real Time Quote from BATS)
$2.09 USD
+0.07 (3.47%)
Updated Jun 27, 2024 03:44 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Brokerage Reports
Innate Pharma S.A. Sponsored ADR [IPHA]
Reports for Purchase
Showing records 21 - 29 ( 29 total )
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Re-Prioritize R&D Over Commercialization; Adjust PT to $11.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Monalizumab Advanced Into Pivotal; COVID-19 Study Expanded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Collaboration Amendment Is Not as Bad as it Looks; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Positive Monalizumab Update at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Monalizumab Phase 2 Update at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Lumoxiti Transition on Target; Catalyst Rich 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Lumoxiti MAA Accepted and on Track for 4Q20 Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Favorable Long-Term Data: A Positive for Lumoxiti Adoption; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Innate Pharma S.A. Sponsored ADR
Industry: Medical - Biomedical and Genetics
Strong Commercial and Clinical Progress; Reiterate Buy; Adjusting to $13.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S